{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:09:17Z","timestamp":1785848957004,"version":"3.56.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Netherlands Organization for Scientific Research (EG)"},{"name":"IRC\/Marie Curie International Fellowship (EG)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.lungcan.2012.07.009","type":"journal-article","created":{"date-parts":[[2012,8,11]],"date-time":"2012-08-11T01:15:13Z","timestamp":1344647713000},"page":"92-99","source":"Crossref","is-referenced-by-count":37,"title":["Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed\u2013carboplatin"],"prefix":"10.1016","volume":"78","author":[{"given":"Marcello","family":"Tiseo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giovannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Tibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Camerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godefridus J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2012.07.009_bib0005","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1200\/JCO.2009.23.5622","article-title":"American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer","volume":"27","author":"Azzoli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.lungcan.2012.07.009_bib0010","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdq189","article-title":"Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"D\u2019Addario","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0015","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0020","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2008.19.1650","article-title":"Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer","volume":"27","author":"Smit","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2012.07.009_bib0025","first-page":"S415","article-title":"Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials","volume":"6","author":"Tiseo","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0030","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1535-7163.MCT-06-0343","article-title":"Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications","volume":"6","author":"Chattopadhyay","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0035","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/JCO.2009.23.6406","article-title":"Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426","volume":"28","author":"Adjei","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0040","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/JTO.0b013e3181ec18c4","article-title":"Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study","volume":"5","author":"Adjei","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0045","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood.V100.10.3832","article-title":"Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia","volume":"100","author":"Laverdi\u00e8re","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.fpc.0000114761.78957.7e","article-title":"A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells","volume":"14","author":"Cheng","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0055","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1517\/13543784.2011.617742","article-title":"Thymidylate synthase inhibitors for non-small cell lung cancer","volume":"20","author":"Galvani","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0060","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1247\/csf.20.191","article-title":"Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5\u2032-terminal regulatory region of the human gene for thymidylate synthase","volume":"20","author":"Horie","year":"1995","journal-title":"Cell Struct Funct"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0065","first-page":"383","article-title":"Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer","volume":"19","author":"Marsh","year":"2001","journal-title":"Int J Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0070","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1200\/JCO.2001.19.6.1779","article-title":"Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer","volume":"19","author":"Villafranca","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0075","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1200\/JCO.2005.06.219","article-title":"Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity","volume":"23","author":"Jakobsen","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0080","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1158\/1078-0432.CCR-04-2428","article-title":"Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy","volume":"11","author":"Kawakami","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0085","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2006.10.4182","article-title":"Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group","volume":"26","author":"Schwab","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0090","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3816\/CCC.2009.n.024","article-title":"Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer","volume":"8","author":"Mauritz","year":"2009","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0095","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1358\/dot.2003.39.10.799471","article-title":"Influence of genetic markers on survival in non-small cell lung cancer","volume":"39","author":"Rosell","year":"2003","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12032-010-9443-1","article-title":"Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis","volume":"28","author":"Wei","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0105","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0110","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1535-7163.MCT-09-0665","article-title":"Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib","volume":"9","author":"Giovannetti","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0115","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ng0595-111","article-title":"A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase","volume":"10","author":"Frosst","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0125","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00280-011-1632-x","article-title":"Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation","volume":"68","author":"Metro","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0130","article-title":"Biomarker analysis in a phase III study of pemetrexed\u2013carboplatin versus etoposide\u2013carboplatin in chemonaive patients with extensive-stage small-cell lung cancer","author":"Smit","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0135","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1200\/JCO.2010.33.3591","article-title":"Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer","volume":"29","author":"Argiris","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0140","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1093\/annonc\/mdr002","article-title":"Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer","volume":"22","author":"Argiris","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0145","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2006.10.4752","article-title":"Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer","volume":"25","author":"Marsh","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0150","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-07-1364","article-title":"Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine\/cisplatin-treated advanced non-small cell lung cancer patients","volume":"1","author":"Tibaldi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0155","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1200\/JCO.2010.29.1559","article-title":"Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?","volume":"28","author":"Buikhuisen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.07.009_bib0160","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/clpt.2010.274","article-title":"Why, when, and how should pharmacogenetics be applied in clinical studies? Current and future approaches to study designs","volume":"89","author":"Stingl Kirchheiner","year":"2011","journal-title":"Clin Pharmacol Ther"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500212004345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500212004345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T09:53:58Z","timestamp":1542794038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500212004345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0169500212004345"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2012.07.009","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}